Immunotherapy biomarkers 2016: overcoming the barriers

Area of Science:

• Oncology
• Immunology
• Biomarker Discovery

Background:

• The field of cancer immunotherapy has rapidly advanced, necessitating the identification and validation of reliable biomarkers.
• Biomarkers are crucial for predicting patient response to immunotherapy and guiding treatment decisions.
• Significant challenges exist in the development and clinical implementation of immunotherapy biomarkers.

Purpose of the Study:

• To summarize the key discussions and outcomes of the 'Immunotherapy Biomarkers 2016: Overcoming the Barriers' symposium.
• To highlight emerging immunotherapy biomarkers and novel technologies for their detection and validation.
• To identify current hurdles in biomarker development and propose recommendations for future progress.

Main Methods:

• The report is a summary of a symposium held on April 1, 2016, at the National Institutes of Health.
• The symposium was cosponsored by the Society for Immunotherapy of Cancer (SITC) and the National Cancer Institute (NCI).
• Discussions focused on emerging biomarkers, new technologies, challenges, and recommendations in cancer immunotherapy.

Main Results:

• Emerging immunotherapy biomarkers and novel technologies were presented and discussed.
• Key barriers to the development and clinical application of biomarkers were identified.
• Recommendations were formulated to accelerate biomarker research and implementation.

Conclusions:

• Advancing immunotherapy biomarker development requires addressing technological, clinical, and regulatory challenges.
• Collaborative efforts between researchers, clinicians, and regulatory bodies are essential.
• The symposium provided a roadmap for overcoming existing barriers and promoting the effective use of biomarkers in cancer immunotherapy.